Higher levels of CA-125 and CA-199 may be more effective than CEA in predicting poor PFS in patients with stage IV adenocarcinoma, with CA-125 demonstrating particular effectiveness in those who received EGFR TKIs. This evidence concerns the gene CEACAM5 and adenocarcinoma.